ArticleCell death and differentiation2012
The Apaf-1-binding protein Aven is cleaved by Cathepsin D to unleash its anti-apoptotic potential.
Article in Cell death and differentiation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- A multiomics Mendelian randomization study on PANoptosis-related genes and gastric cancer risk.The Journal of international medical research · 2026Article
- AVEN: a novel oncogenic biomarker with prognostic significance and implications of AVEN-associated immunophenotypes in lung adenocarcinoma.Frontiers in molecular biosciences · 2023Article
- Molecular mechanism of CAIF inhibiting myocardial infarction by sponging miR‑488 and regulating AVEN expression.Molecular medicine reports · 2022Article
- Differential Neuropeptidomes of Dense Core Secretory Vesicles (DCSV) Produced at Intravesicular and Extracellular pH Conditions by Proteolytic Processing.ACS chemical neuroscience · 2021Article
- Down-regulation of miR-30b-5p protects cardiomyocytes against hypoxia-induced injury by targeting Aven.Cellular & molecular biology letters · 2019Article
- Forkhead-box transcription factor 1 affects the apoptosis of natural regulatory T cells by controlling Aven expression.BMC immunology · 2017Article
- Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Aven recognition of RNA G-quadruplexes regulates translation of the mixed lineage leukemia protooncogenes.eLife · 2015Article
- GRIM REAPER peptide binds to receptor kinase PRK5 to trigger cell death in Arabidopsis.The EMBO journal · 2015Article
- Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites.Clinical and translational medicine · 2015Article
- Aven is dynamically regulated during Xenopus oocyte maturation and is required for oocyte survival.Cell death & disease · 2013Article
- Article
- Proteolytic characteristics of cathepsin D related to the recognition and cleavage of its target proteins.PloS one · 2013Article
- A functional yeast survival screen of tumor-derived cDNA libraries designed to identify anti-apoptotic mammalian oncogenes.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anti-apoptotic molecule Aven was originally identified in a yeast two-hybrid screen for Bcl-x(L)-interacting proteins and has also been found to bind Apaf-1, thereby interfering with Apaf-1 self-association during apoptosome assembly. Aven is expressed in a wide variety of adult tissues and cell lines, and there is increasing evidence that its overexpression correlates with tumorigenesis, particularly in acute leukemias. The mechanism by which the anti-apoptotic activity of Aven is regulated remains poorly understood. Here we shed light on this issue by demonstrating that proteolytic removal of an inhibitory N-terminal Aven domain is necessary to activate the anti-apoptotic potential of the molecule. Furthermore, we identify Cathepsin D (CathD) as the protease responsible for Aven cleavage. On the basis of our results, we propose a model of Aven activation by which its N-terminal inhibitory domain is removed by CathD-mediated proteolysis, thereby unleashing its cytoprotective function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.